The following is the summary of “Safety of Biologics for Atopic Diseases During Pregnancy” published in the December 2022 issue of Allergy and Clinical Immunology by Shakuntulla, et al.

Because of the high prevalence of atopic illnesses in women of reproductive age, there is a pressing need to investigate whether or not biologics are safe to use during pregnancy. This article summarizes the effects of seven biologics approved by the Food and Drug Administration (FDA) on the outcomes for both mothers and their unborn children. These biologics are omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab. 

To achieve this goal, researchers conducted a literature search restricted to publications written in the English language to investigate whether or not the use of biologics during pregnancy for the treatment of atopic diseases increased the risk of premature delivery, stillbirth, low birth weight, or congenital malformations. The majority of tMost of the articles case reports, case series, or observational studies that reported the results of a total of 313 pregnancies. There were no randomized controlled studies that could be found. According to our findings, biologics do not appear to have any effect on the outcomes for either the mother or the baby.

In point of fact, it would appear that aorsening the underlying allergic condition while the mother is pregnant is more damaging to the pregnancy’s chances of success. In light of the limited number of studies and the small size of the samples collected, it is recommended that future research include prospective studies with comparable control groups that were not exposed to any biologics and multicenter registries for long-term follow-up.